We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+6.72%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$616B
AUM Growth
+$31B
Cap. Flow
-$1.19B
Cap. Flow %
-0.19%
Top 10 Hldgs %
18.88%
Holding
2,692
New
121
Increased
947
Reduced
1,282
Closed
130

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$1.86B
2
VMW
VMware, Inc
VMW
+$1.49B
3
AVGO icon
Broadcom
AVGO
+$1.29B
4
SRE icon
Sempra
SRE
+$1.26B
5
BKNG icon
Booking.com
BKNG
+$1.12B

Sector Composition

Rank Sector Weight
1 Healthcare 17.07%
2 Financials 16.19%
3 Technology 16.15%
4 Consumer Discretionary 13.93%
5 Industrials 9.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HHS icon
2576
Harte-Hanks
HHS
$18.5M
-2,975
Closed -$32K
HRTX icon
2577
Heron Therapeutics
HRTX
$61.5M
-15,327
Closed -$248K
ICLR icon
2578
Icon
ICLR
$12.8B
-3,068
Closed -$349K
IMUX icon
2579
Immunic
IMUX
$211M
-44
Closed -$89K
KPTI icon
2580
Karyopharm Therapeutics
KPTI
$47.6M
-926
Closed -$153K
KRG icon
2581
Kite Realty
KRG
$5.24B
-17,534
Closed -$355K
LAB icon
2582
Standard BioTools
LAB
$309M
-14,900
Closed -$75K
KG
2583
Kestrel Group
KG
$68.8M
-1,660
Closed -$264K
NPK icon
2584
National Presto Industries
NPK
$991M
-3,014
Closed -$321K
NTNX icon
2585
Nutanix
NTNX
$17.4B
-35,965
Closed -$805K
NTWK icon
2586
NetSol Technologies
NTWK
$49.9M
-23,500
Closed -$82K
NWG icon
2587
NatWest
NWG
$75.8B
-23,679
Closed -$186K
ACH
2588
Accendra Health
ACH
$96.9M
-21,284
Closed -$621K
OSPN icon
2589
OneSpan
OSPN
$601M
-16,083
Closed -$194K
PAAS icon
2590
Pan American Silver
PAAS
$21.8B
-626,488
Closed -$10.7M
PGEN icon
2591
Precigen
PGEN
$2.46B
-27,967
Closed -$532K
PMT
2592
PennyMac Mortgage Investment
PMT
$824M
-29,190
Closed -$508K
PW
2593
Power REIT
PW
$2.94M
-1,013
Closed -$64K
REFR icon
2594
Research Frontiers
REFR
$17.2M
-31,600
Closed -$38K
RGS icon
2595
Regis Corp
RGS
$68.3M
-780
Closed -$223K
ROKU icon
2596
Roku
ROKU
$22.4B
-1,200,000
Closed -$31.8M
SHM icon
2597
State Street SPDR Nuveen ICE Short Term Municipal Bond ETF
SHM
$3.47B
-17,500
Closed -$851K
SOHO
2598
DELISTED
Sotherly Hotels
SOHO
-14,600
Closed -$86K
TRS icon
2599
TriMas Corp
TRS
$1.43B
-12,920
Closed -$349K
TTSH
2600
DELISTED
Tile Shop Holdings
TTSH
-3,503,431
Closed -$44.5M

Similar funds

T. Rowe Price Associates's Q4 2017 Portfolio in Review

As of Q4 2017, T. Rowe Price Associates held 2,692 positions worth $616B, up 5.3% from $585B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

T. Rowe Price Associates's Q4 2017 filing shows 121 new, 947 increased, 1,282 reduced and 130 closed positions. Its largest new stake was CarGurus: 13,060,603 shares worth $374M. The largest sale was PayPal, an estimated $1.66B.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Financials and Technology.

  • T. Rowe Price Associates's largest Q4 2017 buy was CarGurus: 13,060,603 shares worth $374M.
  • T. Rowe Price Associates added most to Tesla in Q4 2017, an estimated $1.86B increase.
  • T. Rowe Price Associates's biggest Q4 2017 reduction was PayPal, cutting an estimated $1.66B.
  • T. Rowe Price Associates fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $483M.
  • T. Rowe Price Associates's ten largest holdings make up 19% of its $616B portfolio in Q4 2017.
  • T. Rowe Price Associates opened 121 new positions and closed 130 in Q4 2017.
  • T. Rowe Price Associates's portfolio value rose 5.3% quarter-over-quarter to $616B.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.